<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ALMOTRIPTAN MALATE- almotriptan malate tablet, coated </strong><br>Patriot Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Almotriptan Malate tablets safely and effectively. See full prescribing information for Almotriptan Malate tablets.<br><br>Almotriptan Malate tablets for Oral Use<br>Initial U.S. Approval: 2001</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table class="Noautorules" width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left">Warnings and Precautions, Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (<a href="#S5.6">5.6</a>)</td>
<td align="right">08/2014</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Almotriptan Malate is a 5HT<span class="Sub">1B/1D</span> receptor agonist (triptan) indicated for: </p>
<ul class="Disc">
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in adults with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> (<a href="#S1.1">1.1</a>)</li>
<li>Acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in adolescents age 12 to 17 years with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, and who have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks usually lasting 4 hours or more (<a href="#S1.1">1.1</a>)</li>
</ul>
<p class="Highlighta">Important limitations: </p>
<ul class="Disc">
<li>Use only after a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established (<a href="#S1.2">1.2</a>)</li>
<li>In adolescents age 12 to 17 years, efficacy of Almotriptan Malate tablets on <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated symptoms was not established (<a href="#S1.2">1.2</a>)</li>
<li>Not intended for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (<a href="#S1.2">1.2</a>)</li>
<li>Not indicated for the treatment of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> (<a href="#S1.2">1.2</a>)</li>
</ul>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Adults and adolescents age 12 to 17 years: 6.25 mg or 12.5 mg single dose; may repeat after 2 hours if <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> returns; benefit of second dose in patients who have failed to respond to first dose has not been established; maximum daily dose 25 mg (<a href="#S2.1">2.1</a>)</li>
<li>Patients with hepatic or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: 6.25 mg starting dose; maximum daily dose 12.5 mg (<a href="#S2.2">2.2</a>, <a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 6.25 mg and 12.5 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Ischemic heart disease</span>, coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, or other significant underlying cardiovascular disease (<a href="#S4.1">4.1</a>)</li>
<li>Cerebrovascular syndromes (e.g., history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or TIA) (<a href="#S4.2">4.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span> (including ischemic bowel disease) (<a href="#S4.3">4.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled hypertension</span> (<a href="#S4.4">4.4</a>)</li>
<li>Do not use Almotriptan Malate tablets within 24 hours of an ergotamine-containing, or ergot-type medication, or of another 5-HT<span class="Sub">1</span> agonist, e.g., another triptan (<a href="#S4.5">4.5</a>, <a href="#S4.6">4.6</a>)</li>
<li>Hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> (<a href="#S4.7">4.7</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Almotriptan Malate tablets (<a href="#S4.8">4.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> and life-threatening disturbances of cardiac rhythm (<a href="#S5.1">5.1</a>)</li>
<li>It is strongly recommended that Almotriptan Malate tablets not be given to patients in whom unrecognized <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) is predicted by the presence of risk factors. In very rare cases, serious cardiovascular events have been reported in association with Almotriptan Malate tablets use in the absence of known cardiovascular disease. If Almotriptan Malate tablets are considered, patients should first have a cardiovascular evaluation. If the evaluation is satisfactory, first dose should take place in a physician's office setting (<a href="#S5.1">5.1</a>)</li>
<li>Sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, tightness, pressure, and heaviness in the chest, throat, neck, and jaw: generally not associated with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, but patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD (<a href="#S5.2">5.2</a>)</li>
<li>Cerebrovascular events, some fatal (<a href="#S5.3">5.3</a>)</li>
<li>Gastrointestinal ischemic events and peripheral vasospastic reactions (e.g., Raynaud's syndrome) (<a href="#S5.4">5.4</a>)</li>
<li>Potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, particularly in combination with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Monitor patients for <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic changes</span> and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> if concomitant treatment is clinically warranted (<a href="#S5.5">5.5</a>, <a href="#S7.3">7.3</a>)</li>
<li>Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>: Detoxification may be necessary (<a href="#S5.6">5.6</a>)</li>
<li>Increase in blood pressure, very rarely associated with significant clinical events (<a href="#S4.4">4.4</a>, <a href="#S5.7">5.7</a>)</li>
<li>Use with caution in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfonamides (<a href="#S5.8">5.8</a>)</li>
</ul></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (<span class="Underline">≥</span>1% and greater than placebo) are: </p>
<ul class="Disc">
<li>In adults: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (<a href="#S6.1">6.1</a>)</li>
<li>In adolescents: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#S6.2">6.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact 1-800-667-8570 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Do not use Almotriptan Malate tablets and ergotamine-containing or ergot-type medications within 24 hours of each other (<a href="#S4.5">4.5</a>, <a href="#S7.1">7.1</a>)</li>
<li>Do not use Almotriptan Malate tablets and other 5-HT<span class="Sub">1</span> agonists (e.g., triptans) within 24 hours of each other (<a href="#S4.6">4.6</a>, <a href="#S7.2">7.2</a>)</li>
<li>SSRI or SNRI: life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> reported during combined use with triptans (<a href="#S5.5">5.5</a>, <a href="#S7.3">7.3</a>)</li>
<li>Ketoconazole: use single dose of Almotriptan Malate tablets 6.25 mg; maximum Almotriptan Malate tablets daily dose 12.5 mg (<a href="#S7.4">7.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: based on animal data, may cause fetal harm (<a href="#S8.1">8.1</a>)</li>
<li>Nursing mothers:  use Almotriptan Malate tablets with caution  (<a href="#S8.3">8.3</a>)</li>
<li>Pediatric use: Almotriptan Malate tablets have  not been studied in children under 12 years (<a href="#S8.4">8.4</a>)</li>
<li>Geriatric use: insufficient safety and efficacy data; use with caution, usually starting with the 6.25 mg dose (<a href="#S8.5">8.5</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg (<a href="#S2.2">2.2</a>, <a href="#S8.6">8.6</a>)</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: use single 6.25 mg tablet as a starting dose; maximum daily dose 12.5 mg (<a href="#S2.3">2.3</a>, <a href="#S8.7">8.7</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Attacks</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Important Limitations</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Attacks</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1	Ischemic or Vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>, or Other Significant Underlying Cardiovascular Disease</a></h2>
<h2><a href="#section-4.2" class="toc">4.2	Cerebrovascular Syndromes</a></h2>
<h2><a href="#section-4.3" class="toc">4.3	<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></a></h2>
<h2><a href="#section-4.4" class="toc">4.4	<span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled Hypertension</span></a></h2>
<h2><a href="#section-4.5" class="toc">4.5	Ergotamine-Containing and Ergot-Type Medications</a></h2>
<h2><a href="#section-4.6" class="toc">4.6	Concomitant Use With 5-HT<span class="Sub">1</span> Agonists (e.g., Triptans)</a></h2>
<h2><a href="#section-4.7" class="toc">4.7	Hemiplegic or Basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-4.8" class="toc">4.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Cerebrovascular Events and Fatalities</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, Including Peripheral Vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> and Colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Increases in Blood Pressure</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Sulfonamides</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Impaired Hepatic or Renal Function</a></h2>
<h2><a href="#section-5.10" class="toc">5.10	Binding to Melanin-Containing Tissues</a></h2>
<h2><a href="#section-5.11" class="toc">5.11	Corneal Opacities</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Almotriptan Malate Tablets Clinical Trials</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Other Adverse Reactions Observed in Almotriptan Malate Tablets Clinical Trials</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Ergot-Containing Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	5-HT<span class="Sub">1</span> Agonists (e.g., Triptans)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Ketoconazole and Other Potent CYP3A4 Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-9.1" class="toc">10.1	Signs and Symptoms</a></h2>
<h2><a href="#section-9.2" class="toc">10.2	Recommended Treatment</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1	Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2	Adolescents Age 12 to 17 Years</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Attacks</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>Almotriptan Malate tablets are indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in patients with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1.1.2"></a><p></p>
<p class="First"><span class="Underline">Adolescents </span><span class="Underline">Age 12 to 17 Years</span></p>
<p>Almotriptan Malate tablets are indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in patients with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> usually lasting 4 hours or more (when untreated).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Important Limitations</h2>
<p class="First">Almotriptan Malate tablets should only be used where a clear diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> has been established. If a patient has no response for the first <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack treated with Almotriptan Malate tablets, the diagnosis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> should be reconsidered before Almotriptan Malate tablets are administered to treat any subsequent attacks.</p>
<p>In adolescents age 12 to 17 years, efficacy of Almotriptan Malate tablets on <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>) was not established. Almotriptan Malate tablets are not intended for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or for use in the management of hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="Italics">[see <a href="#S4.7">Contraindications (4.7)</a>]</span>.</p>
<p>Safety and effectiveness of Almotriptan Malate tablets have not been established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span> which is present in an older, predominantly male population.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Attacks</h2>
<p class="First">The recommended dose of Almotriptan Malate tablets in adults and adolescents age 12 to 17 years is 6.25 mg to 12.5 mg, with the 12.5 mg dose tending to be a more effective dose in adults. As individuals may vary in their response to different doses of Almotriptan Malate tablets, the choice of dose should be made on an individual basis.</p>
<p>If the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> is relieved after the initial Almotriptan Malate tablets dose but returns, the dose may be repeated after 2 hours. The effectiveness of a second dose has not been established in placebo-controlled trials. The maximum daily dose should not exceed 25 mg. The safety of treating an average of more than four <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> in a 30-day period has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The recommended starting dose of Almotriptan Malate tablets in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The recommended starting dose of Almotriptan Malate tablets in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Almotriptan Malate tablets are available as white, coated, circular, biconvex tablets in the following dosage strengths:</p>
<p>6.25 mg tablet with red code imprint "2080"</p>
<p>12.5 mg tablet with blue stylized imprint "A."</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1	Ischemic or Vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span>, or Other Significant Underlying Cardiovascular Disease</h2>
<p class="First">Do not use Almotriptan Malate tablets in patients with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or documented silent <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>), or in patients who have symptoms or findings consistent with <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, including Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span>, or other significant underlying cardiovascular disease <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2	Cerebrovascular Syndromes</h2>
<p class="First">Do not use Almotriptan Malate tablets in patients with cerebrovascular syndromes including (but not limited to) <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> of any type as well as <span class="product-label-link" type="condition" conceptid="373503" conceptname="Transient cerebral ischemia">transient ischemic attacks</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.3"></a><a name="section-4.3"></a><p></p>
<h2>4.3	<span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral Vascular Disease</span></h2>
<p class="First">Do not use Almotriptan Malate tablets in patients with <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> including (but not limited to) ischemic bowel disease <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.4"></a><a name="section-4.4"></a><p></p>
<h2>4.4	<span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">Uncontrolled Hypertension</span></h2>
<p class="First">Because Almotriptan Malate tablets may increase blood pressure, do not use Almotriptan Malate tablets in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.5"></a><a name="section-4.5"></a><p></p>
<h2>4.5	Ergotamine-Containing and Ergot-Type Medications</h2>
<p class="First">Do not use Almotriptan Malate tablets and ergotamine-containing or ergot-derived medications like dihydroergotamine, ergotamine tartrate, or methysergide within 24 hours of each other <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.6"></a><a name="section-4.6"></a><p></p>
<h2>4.6	Concomitant Use With 5-HT<span class="Sub">1</span> Agonists (e.g., Triptans)</h2>
<p class="First">Almotriptan Malate tablets and other 5-HT<span class="Sub">1</span> agonists (e.g., triptans) should not be administered within 24 hours of each other <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a> and <a href="#S5.2">(5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.7"></a><a name="section-4.7"></a><p></p>
<h2>4.7	Hemiplegic or Basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">Do not use Almotriptan Malate tablets in patients with hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S4.8"></a><a name="section-4.8"></a><p></p>
<h2>4.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Almotriptan Malate tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to almotriptan or any of its inactive ingredients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Underline">Cardiac Events and Fatalities with 5-HT<span class="Sub">1</span> Agonists</span></p>
<p>Serious adverse cardiac events, including <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, have been reported within a few hours following administration of Almotriptan Malate tablets. Life-threatening disturbances of cardiac rhythm and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported within a few hours following the administration of other triptans. Considering the extent of use of triptans in patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, the incidence of these events is extremely low.</p>
<p>Almotriptan Malate tablets can cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>; at least one of these events occurred in a patient with no cardiac history and with documented absence of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Because of the close proximity of the events to use of Almotriptan Malate tablets, a causal relationship cannot be excluded. Patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (CAD) or a predisposition to Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms recur.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Premarketing Experience with Almotriptan Malate tablets in Adults</span></p>
<p>Among the 3865 subjects/patients who received Almotriptan Malate tablets in premarketing clinical trials, one patient was hospitalized for observation after a scheduled electrocardiogram (ECG) was found to be abnormal (negative T-waves on the left leads) 48 hours after taking a single 6.25 mg dose of almotriptan. The patient, a 48-year-old female, had previously taken 3 other doses for earlier <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Myocardial enzymes at the time of the <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span> were normal. The patient was diagnosed as having had <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and that she had a family history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary disease</span>. An ECG performed 2 days later was normal, as was a follow-up coronary angiography. The patient recovered without incident.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Postmarketing Experience with Almotriptan Malate tablets in Adults</span></p>
<p>Serious cardiovascular events have been reported in association with the use of Almotriptan Malate tablets. The uncontrolled nature of postmarketing surveillance, however, makes it impossible to definitively determine the proportion of the reported cases that were actually caused by almotriptan or to reliably assess causation in individual cases <span class="Italics">[see <a href="#S6.3">Adverse Reactions (6.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1.3"></a><p></p>
<p class="First"><span class="Italics">Patients with Documented <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary Artery Disease</span></span></p>
<p>Because of the potential of this class of compound (5-HT<span class="Sub">1</span> agonists) to cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>, Almotriptan Malate tablets should not be given to patients with documented ischemic or vasospastic <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1.4"></a><p></p>
<p class="First"><span class="Italics">Patients with Risk Factors for CAD</span></p>
<p>It is strongly recommended that Almotriptan Malate tablets are not given to patients in whom unrecognized CAD is predicted by the presence of risk factors (e.g., <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, smoker, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, strong family history of CAD, female with surgical or physiological <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, or male over 40 years of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of coronary artery and ischemic myocardial disease or other significant underlying cardiovascular disease. The sensitivity of cardiac diagnostic procedures to detect cardiovascular disease or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest, at best. If, during the cardiovascular evaluation, the patient's medical history, electrocardiographic or other investigations reveal findings indicative of, or consistent with, coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, Almotriptan Malate tablets should not be administered <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a>]</span>.</p>
<p>For patients with risk factors predictive of CAD, who are determined to have a satisfactory cardiovascular evaluation, it is strongly recommended that administration of the first dose of Almotriptan Malate tablets take place in the setting of a physician's office or similar medically staffed and equipped facility unless the patient has previously received Almotriptan Malate tablets. Because <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span> can occur in the absence of clinical symptoms, consideration should be given to obtaining on the first occasion of use an ECG during the interval immediately following Almotriptan Malate tablets, in these patients with risk factors. It is recommended that patients who are intermittent long-term users of Almotriptan Malate tablets and who have or acquire risk factors predictive of CAD, as described above, undergo periodic interval cardiovascular evaluation as they continue to use Almotriptan Malate tablets.</p>
<p>The systematic approach described above is intended to reduce the likelihood that patients with unrecognized cardiovascular disease will be inadvertently exposed to Almotriptan Malate tablets. The ability of cardiac diagnostic procedures to detect all cardiovascular diseases or predisposition to coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> is modest at best. Cardiovascular events associated with triptan treatment have occurred in patients with no cardiac history and with documented absence of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw</h2>
<p class="First">As with other 5-HT<span class="Sub">1</span> agonists, sensations of tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported after treatment with Almotriptan Malate tablets. Because 5-HT<span class="Sub">1</span> agonists may cause <span class="product-label-link" type="condition" conceptid="4127089" conceptname="Coronary artery spasm">coronary vasospasm</span>, patients who experience signs or symptoms suggestive of angina following dosing should be evaluated for the presence of CAD or a predisposition to Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> before receiving additional doses of medication, and should be monitored electrocardiographically if dosing is resumed and similar symptoms occur. Patients shown to have CAD and those with Prinzmetal's <span class="product-label-link" type="condition" conceptid="315830" conceptname="Prinzmetal angina">variant angina</span> should not receive 5-HT<span class="Sub">1</span> agonists <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Cerebrovascular Events and Fatalities</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and other cerebrovascular events have been reported in patients treated with other triptans and some events have resulted in fatalities. In a number of cases, it appeared possible that the cerebrovascular events were primary, the triptan having been administered in the incorrect belief that the symptoms experienced were a consequence of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, when they were not. As with other <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> therapies, before treating <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> in patients not previously diagnosed as migraineurs and in migraineurs who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions. It should be noted that patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> may be at increased risk of certain cerebrovascular events (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and transient ischemic attack) <span class="Italics">[see <a href="#S4.2">Contraindications (4.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, Including Peripheral Vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> and Colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span></h2>
<p class="First">Triptans, including Almotriptan Malate tablets, may cause vasospastic reactions other than coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, such as peripheral and gastrointestinal vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>. Very rare reports of transient and permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> and significant partial <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span> have been reported with the use of triptans. Visual disorders may also be part of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Patients who experience symptoms or signs suggestive of decreased arterial flow following the use of any triptan, such as ischemic bowel syndrome or Raynaud's syndrome, are candidates for further evaluation <span class="Italics">[see <a href="#S4.3">Contraindications (4.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></h2>
<p class="First">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with triptans, including Almotriptan Malate tablets, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If concomitant treatment with Almotriptan Malate tablets and an SSRI (e.g., fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram) or SNRI (e.g., venlafaxine, duloxetine) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> symptoms may include <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span> (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>) <span class="Italics">[See <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Overuse of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). Medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> may present as <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-like daily <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or as a marked increase in frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>) may be necessary.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Increases in Blood Pressure</h2>
<p class="First">As with other triptans, significant elevations in systemic blood pressure have been reported on rare occasions with Almotriptan Malate tablets use in patients with and without a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; very rarely these increases in blood pressure have been associated with significant clinical events. Almotriptan Malate tablets are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> <span class="Italics">[see <a href="#S4.4">Contraindications (4.4)</a>]</span>. In normotensive healthy subjects and patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> controlled by medication, small, but clinically insignificant, increases in mean systolic (0.21 and 4.87 mm Hg, respectively) and diastolic (1.35 and 0.26 mm Hg, respectively) blood pressure relative to placebo were seen over the first 4 hours after oral administration of 12.5 mg of almotriptan.</p>
<p>An 18% increase in mean pulmonary artery pressure was seen following dosing with another triptan in a study evaluating subjects undergoing cardiac catheterization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Sulfonamides</h2>
<p class="First">Caution should be exercised when prescribing Almotriptan Malate tablets to patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sulfonamides. The chemical structure of almotriptan contains a sulfonyl group, which is structurally different from a sulfonamide. Cross-sensitivity to almotriptan in patients allergic to sulfonamides has not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Impaired Hepatic or Renal Function</h2>
<p class="First">Almotriptan Malate tablets should be administered with caution to patients with diseases that may alter the absorption, metabolism, or excretion of drugs, such as those with impaired hepatic or renal function <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S2.3">(2.3)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	Binding to Melanin-Containing Tissues</h2>
<p class="First">When pigmented rats were given a single oral dose of 5 mg/kg of radiolabeled almotriptan, the elimination half-life of radioactivity from the eye was 22 days. This finding suggests that almotriptan and/or its metabolites may bind to melanin in the eye. Because almotriptan could accumulate in melanin-rich tissues over time, there is the possibility that it could cause toxicity in these tissues with extended use. However, no adverse retinal effects related to treatment with almotriptan were noted in a 52-week toxicity study in dogs given up to 12.5 mg/kg/day (resulting in exposure [AUC] to parent drug approximately 20 times that in humans receiving the maximum recommended human dose of 25 mg/day). Although no systematic monitoring of ophthalmologic function was undertaken in clinical trials, and no specific recommendations for ophthalmologic monitoring are offered, prescribers should be aware of the possibility of long-term ophthalmologic effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	Corneal Opacities</h2>
<p class="First">Three male dogs (out of a total of 14 treated) in a 52-week toxicity study of oral almotriptan developed slight corneal opacities that were noted after 51 weeks, but not after 25 weeks of treatment. The doses at which this occurred were 2, 5, and 12.5 mg/kg/day. The opacity reversed after a 4-week drug-free period in the affected dog treated with the highest dose. Systemic exposure (plasma AUC) to parent drug at 2 mg/kg/day was approximately 2.5 times the exposure in humans receiving the maximum recommended human daily dose of 25 mg. A no-effect dose was not established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, have occurred following the use of Almotriptan Malate tablets. These reactions are extremely rare and most have been reported in patients with risk factors predictive of CAD. Reactions reported in association with triptans have included coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, transient <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> <span class="Italics">[see <a href="#S4.1">Contraindications (4.1)</a> and <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<p>The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span> and Other Adverse Cardiac Events <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Sensations of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, Tightness, Pressure in the Chest and/or Throat, Neck, and Jaw <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Cerebrovascular Events and Fatalities <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, Including Peripheral Vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> and Colonic <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">Ischemia</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Increases in Blood Pressure <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
</ul>
<p>Adverse events were assessed in controlled clinical trials that included 1840 adult patients who received one or two doses of Almotriptan Malate tablets and 386 adult patients who received placebo. The most common adverse reactions during treatment with Almotriptan Malate tablets were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>. In long-term open-label studies where patients were allowed to treat multiple attacks for up to 1 year, 5% (63 out of 1347 patients) withdrew due to adverse experiences.</p>
<p>Adverse events were assessed in controlled clinical trials that included 362 adolescent patients who received Almotriptan Malate tablets and 172 adolescent patients who received placebo. The most common adverse reactions during treatment with Almotriptan Malate tablets were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In a long-term, open-label study where patients were allowed to treat multiple attacks for up to 1 year, 2% (10 out of 420 adolescent patients) withdrew due to adverse events.</p>
<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Almotriptan Malate Tablets Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults</span></p>
<p>Table 1 lists the adverse events that occurred in at least 1% of the adult patients treated with Almotriptan Malate tablets, and at an incidence greater than in patients treated with placebo, regardless of drug relationship.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table  1. Incidence of Adverse Events in Controlled Clinical Trials (Reported in  at Least 1% of Adult Patients Treated with Almotriptan Malate tablets, and at an Incidence Greater than Placebo)</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<thead><tr class="First Last">
<th align="left" valign="middle">System/Organ Class<br>  Adverse Event</th>
<th align="center">Almotriptan Malate tablets 6.25 mg<br>(n=527)<br>%</th>
<th align="center">Almotriptan Malate tablets 12.5 mg<br>(n=1313)<br>%</th>
<th align="center">Placebo<br>(n=386)<br>%</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Digestive Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0.5</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">0.5</td>
</tr>
</tbody>
</table>
<p>The incidence of adverse events in controlled clinical trials was not affected by gender, weight, age, presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, or use of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> medications or oral contraceptives. There were insufficient data to assess the effect of race on the incidence of adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline">Adolescents</span></p>
<p>Table 2 lists the adverse reactions reported by 1% or more of Almotriptan Malate tablets-treated adolescents age 12 to 17 years in 1 placebo-controlled, double-blind clinical trial.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table  2. Adverse Reactions Reported by ≥1%  of Adolescent Patients Treated with Almotriptan Malate tablets in  1 Placebo-Controlled, Double-Blind Clinical Trial</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<thead><tr class="Botrule First Last">
<th align="left">System/Organ Class<br>  Adverse Reaction</th>
<th align="center">Almotriptan Malate tablets 6.25 mg<br>(n=180)<br>%</th>
<th align="center">Almotriptan Malate tablets 12.5 mg<br>(n=182)<br>%</th>
<th align="center">Placebo<br>(n=172)<br>%</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">&lt;1</td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">&lt;1</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Other Adverse Reactions Observed in Almotriptan Malate Tablets Clinical Trials</h2>
<p class="First">In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. The reports include adverse reactions in 5 adult controlled studies and 1 adolescent controlled study. Variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used Almotriptan Malate tablets and reported a reaction divided by the total number of patients exposed to Almotriptan Malate tablets (n=3047, all doses). All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within system organ class and enumerated in order of decreasing frequency using the following definitions: frequent adverse reactions are those occurring in 1/100  or more patients, infrequent adverse reactions are those occurring in fewer than 1/100 to 1/1000 patients, and rare adverse reactions are those occurring in fewer than 1/1000 patients.</p>
<p>Body: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal cramp</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>, and Rigid neck. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">Photosensitivity reaction</span>.</p>
<p>Cardiovascular: <span class="Italics">Infrequent:</span> Vasodilation, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>.</p>
<p>Digestive: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span>, and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Increased thirst</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Esophageal reflux</span>, and <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Increased salivation</span>.</p>
<p>Metabolic: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and Increased serum creatine phosphokinase. <span class="Italics">Rare:</span> Increased gamma glutamyl transpeptidase and <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesteremia</span>.</p>
<p>Musculo-Skeletal: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span>, and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>.</p>
<p>Nervous: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, CNS stimulation, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Shakiness</span>. <span class="Italics">Rare:</span> Change in dreams, Impaired concentration, Abnormal coordination, <span class="product-label-link" type="condition" conceptid="4191716" conceptname="Symptoms of depression">Depressive symptoms</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">Hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">Nightmares</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>.</p>
<p>Respiratory: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngismus</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">Hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">Laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">Sneezing</span>, and <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>.</p>
<p>Skin: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>.</p>
<p>Special Senses: <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span> and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry eyes</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">Eye pain</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">Parosmia</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">Scotoma</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">Eye irritation</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">Hyperacusis</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste alteration</span>.</p>
<p>Urogenital: <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">Dysmenorrhea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Almotriptan Malate tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>)</p>
<p>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">Hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">Blepharospasm</span>, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Visual impairment</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></p>
<p>Ear and Labyrinth Disorders: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">Acute myocardial infarction</span>, Coronary artery <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">Hypoesthesia oral</span>, <span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen tongue</span></p>
<p>Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">Cold sweat</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></p>
<p>Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></p>
<p>General Disorders: <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">Peripheral coldness</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Ergot-Containing Drugs</h2>
<p class="First">These drugs have been reported to cause prolonged vasospastic reactions. Because, in theory, vasospastic effects may be additive, ergotamine-containing or ergot-type medications (like dihydroergotamine, ergotamine tartrate, or methysergide) and Almotriptan Malate tablets should not be used within 24 hours of each other <span class="Italics">[see <a href="#S4.5">Contraindications (4.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	5-HT<span class="Sub">1</span> Agonists (e.g., Triptans)</h2>
<p class="First">Concomitant use of other 5-HT<span class="Sub">1</span> agonists (e.g., triptans) within 24 hours of treatment with Almotriptan Malate tablets is contraindicated <span class="Italics">[see <a href="#S4.6">Contraindications (4.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors</h2>
<p class="First">Cases of life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> have been reported during combined use of triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Ketoconazole and Other Potent CYP3A4 Inhibitors</h2>
<p class="First">Co-administration of almotriptan and oral ketoconazole, a potent CYP3A4 inhibitor, resulted in an approximately 60% increase in exposure of almotriptan. Increased exposures to almotriptan may be expected when almotriptan is used concomitantly with other potent CYP3A4 inhibitors <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>In patients concomitantly using potent CYP3A4 inhibitors, the recommended starting dose of Almotriptan Malate tablets is 6.25 mg. The maximum daily dose should not exceed 12.5 mg within a 24-hour period. Concomitant use of Almotriptan Malate tablets and potent CYP3A4 inhibitors should be avoided in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Category C</span></p>
<p>In animal studies, almotriptan produced developmental toxicity (increased embryolethality and fetal skeletal variations, and decreased offspring body weight) at doses greater than those used clinically. There are no adequate and well-controlled studies in pregnant women; therefore, Almotriptan Malate tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>When almotriptan (125, 250, 500, or 1000 mg/kg/day) was administered orally to pregnant rats throughout the period of organogenesis, increased incidences of fetal skeletal variations (decreased ossification) were noted at a dose of 250 mg/kg/day or greater and an increase in embryolethality was seen at the highest dose. The no-effect dose for embryo-fetal developmental toxicity in rats (125 mg/kg/day) is approximately 100 times the maximum recommended human dose (MRHD) of 25 mg/day on a body surface area (mg/m<span class="Sup">2</span>) basis. Similar studies in pregnant rabbits conducted with almotriptan (oral doses of 5, 20, or 60 mg/kg/day) demonstrated increases in embryolethality at the highest dose. The no-effect dose for embryo-fetal developmental toxicity in rabbits (20 mg/kg/day) is approximately 15 times the MRHD on a mg/m<span class="Sup">2</span> basis. When almotriptan (25, 100, or 400 mg/kg/day) was administered orally to rats throughout the periods of gestation and lactation, gestation length was increased and litter size and offspring body weight were decreased at the highest dose. The decrease in pup weight persisted throughout lactation. The no-effect dose in this study (100 mg/kg/day) is 40 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of Almotriptan Malate tablets on labor and delivery in humans is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether almotriptan is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Almotriptan Malate tablets are administered to a nursing woman. Levels of almotriptan in rat milk were up to 7 times higher than in rat plasma.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy of Almotriptan Malate tablets in pediatric patients under the age of 12 years have not been established. The pharmacokinetics, efficacy, and safety of Almotriptan Malate tablets have been evaluated in adolescent patients, age 12 to 17 years <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a> and <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>In a clinical study, Almotriptan Malate 6.25 mg and 12.5 mg tablets were found to be effective for the relief of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in adolescent patients age 12 to 17 years. Efficacy on <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>) was not established. The most common adverse reactions (incidence of ≥1%) associated with Almotriptan Malate tablets treatment were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>. The safety and tolerability profile of Almotriptan Malate tablets treatment in adolescents is similar to the profile observed in adults.</p>
<p>Postmarketing experience with other triptans include a limited number of reports that describe pediatric patients who have experienced clinically serious adverse events that are similar in nature to those reported rarely in adults.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of Almotriptan Malate tablets did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. Clearance of almotriptan was lower in elderly volunteers than in younger individuals, but there were no observed differences in the safety and tolerability between the two populations <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. In general, dose selection for an elderly patient should be cautious, usually starting at the low dose, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The recommended dose of Almotriptan Malate tablets for elderly patients with normal renal function for their age is the same as that recommended for younger adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The recommended starting dose of Almotriptan Malate tablets in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The recommended starting dose of Almotriptan Malate tablets in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over a 24-hour period <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.1"></a><a name="section-9.1"></a><p></p>
<h2>10.1	Signs and Symptoms</h2>
<p class="First">Patients and volunteers receiving single oral doses of 100 to 150 mg of almotriptan did not experience significant adverse events. Six additional normal volunteers received single oral doses of 200 mg without serious adverse events. During clinical trials with Almotriptan Malate tablets, one patient ingested 62.5 mg in a 5-hour period and another patient ingested 100 mg in a 38-hour period. Neither patient experienced adverse reactions.</p>
<p>Based on the pharmacology of triptans, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or other more serious cardiovascular symptoms could occur after overdosage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S10.2"></a><a name="section-9.2"></a><p></p>
<h2>10.2	Recommended Treatment</h2>
<p class="First">There is no specific antidote to Almotriptan Malate tablets. In cases of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system.</p>
<p>Clinical and electrocardiographic monitoring should be continued for at least 20 hours even if clinical symptoms are not observed.</p>
<p>It is unknown what effect hemodialysis or peritoneal dialysis has on plasma concentrations of almotriptan.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Almotriptan Malate tablets contain almotriptan malate, a selective 5-hydroxytryptamine<span class="Sub">1B/1D</span> (5-HT<span class="Sub">1B/1D</span>) receptor agonist. Almotriptan malate is chemically designated as 1-[[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]sulfonyl]pyrrolidine (±)-hydroxybutanedioate (1:1) and its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-01.jpg"></div>
<p>Its empirical formula is C<span class="Sub">17</span>H<span class="Sub">25</span>N<span class="Sub">3</span>O<span class="Sub">2</span>S-C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">5</span>, representing a molecular weight of 469.56. Almotriptan is a white to slightly yellow crystalline powder that is soluble in water. Almotriptan Malate tablets for oral administration contain almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: carnauba wax, cellulose, FD&amp;C Blue No. 2 (12.5 mg only), hypromellose, iron oxide (6.25 mg only), mannitol, polyethylene glycol, povidone, propylene glycol, sodium starch glycolate, sodium stearyl fumarate and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Almotriptan binds with high affinity to 5-HT<span class="Sub">1D</span>, 5-HT<span class="Sub">1B</span>, and 5-HT<span class="Sub">1F</span> receptors. Almotriptan has weak affinity for 5-HT<span class="Sub">1A</span> and 5-HT<span class="Sub">7 </span>receptors, but has no significant affinity or pharmacological activity at 5-HT<span class="Sub">2</span>, 5-HT<span class="Sub">3</span>, 5-HT<span class="Sub">4</span>, 5-HT<span class="Sub">6</span>; alpha or beta adrenergic; adenosine (A<span class="Sub">1</span>, A<span class="Sub">2</span>); angiotensin (AT<span class="Sub">1</span>, AT<span class="Sub">2</span>); dopamine (D<span class="Sub">1</span>, D<span class="Sub">2</span>); endothelin (ET<span class="Sub">A</span>, ET<span class="Sub">B</span>); or tachykinin (NK<span class="Sub">1</span>, NK<span class="Sub">2</span>, NK<span class="Sub">3</span>) binding sites.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Current theories on the etiology of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> suggest that symptoms are due to local cranial <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and/or to the release of vasoactive and pro-inflammatory peptides from sensory nerve endings in an activated trigeminal system. The therapeutic activity of almotriptan in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> can most likely be attributed to agonist effects at 5-HT<span class="Sub">1B/1D </span>receptors on the extracerebral, intracranial blood vessels that become dilated during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack and on nerve terminals in the trigeminal system. Activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release, and reduced transmission in trigeminal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> pathways.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The absolute bioavailability of almotriptan is about 70%, with peak plasma levels occurring 1 to 3 hours after administration; food does not affect pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Underline">Distribution</span></p>
<p>Almotriptan is minimally protein bound (approximately 35%) and the mean apparent volume of distribution is approximately 180 to 200 liters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Underline">Metabolism</span></p>
<p>Almotriptan is metabolized by two major and one minor pathways. Monoamine oxidase (MAO)-mediated oxidative deamination (approximately 27% of the dose), and cytochrome P450-mediated oxidation (approximately 12% of the dose) are the major routes of metabolism, while flavin monooxygenase is the minor route. MAO-A is responsible for the formation of the indoleacetic acid metabolite, whereas cytochrome P450 (3A4 and 2D6) catalyzes the hydroxylation of the pyrrolidine ring to an intermediate that is further oxidized by aldehyde dehydrogenase to the gamma-aminobutyric acid derivative. Both metabolites are inactive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Underline">Excretion</span></p>
<p>Almotriptan has a mean half-life of 3 to 4 hours. Almotriptan is eliminated primarily by renal excretion (about 75% of the oral dose), with approximately 40% of an administered dose excreted unchanged in urine. Renal clearance exceeds the glomerular filtration rate by approximately 3-fold, indicating an active mechanism. Approximately 13% of the administered dose is excreted via feces, both unchanged and metabolized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Underline">Drug-Drug Interactions</span></p>
<p>All drug interaction studies were performed in healthy volunteers using a single 12.5 mg dose of almotriptan and multiple doses of the other drug.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Monoamine Oxidase Inhibitors</span></p>
<p>Co-administration of almotriptan and moclobemide (150 mg twice daily for 8 days) resulted in a 27% decrease in almotriptan clearance and an increase in C<span class="Sub">max</span> of approximately 6%. No dose adjustment is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Propranolol</span></p>
<p>Co-administration of almotriptan and propranolol (80 mg twice daily for 7 days) resulted in no significant changes in the pharmacokinetics of almotriptan.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics">Fluoxetine</span></p>
<p>Co-administration of almotriptan and fluoxetine (60 mg daily for 8 days), a potent inhibitor of CYP2D6, had no effect on almotriptan clearance, but maximal concentrations of almotriptan were increased 18%. This difference is not clinically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Verapamil</span></p>
<p>Co-administration of almotriptan and verapamil (120 mg sustained-release tablets twice daily for 7 days), an inhibitor of CYP3A4, resulted in a 20% increase in the area under the plasma concentration-time curve, and in a 24% increase in maximal plasma concentrations of almotriptan. Neither of these changes is clinically significant. No dose adjustment is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics">Ketoconazole and other Potent CYP3A4 Inhibitors</span></p>
<p>Co-administration of almotriptan and ketoconazole, a potent CYP3A4 inhibitor, resulted in an approximately 60% increase in exposure of almotriptan. Increased exposures to almotriptan may be expected when almotriptan is used with other potent CYP3A4 inhibitors.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Italics">Geriatric</span></p>
<p>Renal and total clearance, and amount of drug excreted in the urine, were lower in elderly healthy volunteers (age 65 to 76 years) than in younger healthy volunteers (age 19 to 34 years), resulting in longer terminal half-life (3.7 hours vs. 3.2 hours) and a 25% higher area under the plasma concentration-time curve in the elderly subjects. The differences, however, do not appear to be clinically significant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.2"></a><p></p>
<p class="First"><span class="Italics">Pediatric</span></p>
<p>A pharmacokinetics study of almotriptan was conducted in adolescents (12 to 17 years) and adults (18 to 55 years) with or without a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. No differences were observed in the rate or extent of absorption of almotriptan in adolescents compared with adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.3"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>No significant gender differences were observed in pharmacokinetic parameters.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.4"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>No significant differences were observed in pharmacokinetic parameters between Caucasian and African-American volunteers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of almotriptan have not been assessed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Based on the known mechanisms of clearance of almotriptan, the maximum decrease expected in almotriptan clearance due to <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> would be 60% <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6.6"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The clearance of almotriptan was approximately 65% lower in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl/F=19.8 L/hour; creatinine clearance between 10 and 30 mL/min) and approximately 40% lower in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (Cl/F=34.2 L/hour; creatinine clearance between 31 and 71 mL/min) than in healthy volunteers (Cl/F=57 L/hour). Maximal plasma concentrations of almotriptan increased by approximately 80% in these patients <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>].</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Almotriptan was administered to mice and rats for up to 103–104 weeks at oral doses up to 250 mg/kg/day and 75 mg/kg/day, respectively. These doses were associated with plasma exposures (AUC) to parent drug that were approximately 40 and 80 times, in mice and rats respectively, the plasma AUC in humans at the maximum recommended human dose (MRHD) of 25 mg/day. Because of high mortality rates in both studies, which reached statistical significance in high-dose female mice, all female rats, all male mice, and high-dose female mice were terminated between weeks 96 and 98. There was no increase in tumors related to almotriptan administration.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Underline">Mutagenesis</span></p>
<p>Almotriptan was not mutagenic in two <span class="Italics">in vitro </span>gene mutation assays, the Ames test, and the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk assay. Almotriptan was not clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Underline">Impairment of Fertility</span></p>
<p>When male and female rats received almotriptan (25, 100, or 400 mg/kg/day) orally prior to and during mating and gestation, prolongation of the estrous cycle was observed at the mid-dose and greater, and fertility was impaired at the highest dose. Subsequent mating of treated with untreated animals indicated that the decrease in fertility was due to an effect on females. The no-effect dose for reproductive toxicity in rats (25 mg/kg/day) is approximately 10 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Adults</h2>
<p class="First">The efficacy of Almotriptan Malate tablets was established in three multi-center, randomized, double-blind, placebo-controlled European trials. Patients enrolled in these studies were primarily female (86%) and Caucasian (more than 98%), with a mean age of 41 years (range of 18 to 72). Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Two hours after taking one dose of study medication, patients evaluated their <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. If the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> had not decreased in severity to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, the patient was allowed to take an escape medication. If the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> had decreased to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at 2 hours but subsequently increased in severity between 2 and 24 hours, it was considered a relapse and the patient was instructed to take a second dose of study medication. Associated symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also evaluated.</p>
<p>In these studies, the percentage of patients achieving a response (mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) 2 hours after treatment was significantly greater in patients who received either Almotriptan Malate tablets 6.25 mg or 12.5 mg, compared with those who received placebo. A higher percentage of patients reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief after treatment with the 12.5 mg dose than with the 6.25 mg dose. Doses greater than 12.5 mg did not lead to a significantly better response. These results are summarized in Table 3.</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3. Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> in Adults</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center" valign="middle">Placebo</th>
<th align="center">Almotriptan Malate tablets<br>6.25 mg</th>
<th align="center">Almotriptan Malate tablets<br>12.5 mg</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>p value 0.002 in comparison with placebo</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p value &lt;0.001 in comparison with placebo</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>p value 0.008 in comparison with placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Study 1</td>
<td align="center">33.8%<br>(n = 80)</td>
<td align="center">55.4%<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a><br>(n = 166)</td>
<td align="center">58.5%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br>(n = 164)</td>
</tr>
<tr>
<td align="left">Study 2</td>
<td align="center">40.0%<br>(n = 95)</td>
<td align="center">---</td>
<td align="center">57.1%<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a><br>(n =175)</td>
</tr>
<tr class="Last">
<td align="left">Study 3</td>
<td align="center">33.0%<br>(n = 176)</td>
<td align="center">55.6%<a href="#footnote-2" class="Sup">†</a><br>(n = 360)</td>
<td align="center">64.9%<a href="#footnote-2" class="Sup">†</a><br>(n = 370)</td>
</tr>
</tbody>
</table>
<p>The estimated probability of achieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief within 2 hours following initial treatment with Almotriptan Malate tablets in adults is shown in Figure 1.</p>
<p><span class="Bold">Figure 1.  Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>) in 2 Hours in Adults</span></p>
<div class="Figure"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-02.jpg"></div>
<p>This Kaplan-Meier plot is based on data obtained in the three placebo-controlled clinical trials that provided evidence of efficacy (Studies 1, 2, and 3). Patients not achieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief by 2 hours were censored at 2 hours.</p>
<p>For patients with <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> at baseline, there was a decreased incidence of these symptoms following administration of Almotriptan Malate tablets compared with placebo.</p>
<p>Two to 24 hours following the initial dose of study medication, patients were allowed to take an escape medication or a second dose of study medication for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> response. The estimated probability of patients taking escape medication or a second dose of study medication over the 24 hours following the initial dose of study medication is shown in Figure 2.</p>
<p><span class="Bold">Figure 2.    Estimated Probability of Adult Patients Taking Escape Medication or a Second Dose of Study Medication Over the 24 Hours Following the Initial Dose of Study Treatment</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-03.jpg"></div>
<p>This Kaplan-Meier plot is based on data obtained in the three placebo-controlled trials that provided evidence of efficacy (Studies 1, 2, and 3). Patients not using additional treatment were censored at 24 hours. Remedication was not allowed within 2 hours after the initial dose of Almotriptan Malate tablets.</p>
<p>The efficacy of Almotriptan Malate tablets was unaffected by the presence of <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>; by gender, weight, or age of the patient; or by concomitant use of common <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> drugs (e.g., beta-blockers, calcium channel blockers, and tricyclic antidepressants); or oral contraceptives. There were insufficient data to assess the effect of race on efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2	Adolescents Age 12 to 17 Years</h2>
<p class="First">The efficacy of Almotriptan Malate tablets in adolescent patients age 12 to 17 years was evaluated in a double-blind, randomized, placebo-controlled study. Patients enrolled in that study had at least a 1-year history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> usually lasting 4 hours or more (when untreated). Patients enrolled in the study were primarily females (60%) and Caucasian (75%), while 15% of patients were black, and 10% were of other races. Patients were instructed to treat a moderate to severe <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Two hours after taking one dose of study medication, patients evaluated their <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Associated symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also evaluated.</p>
<p>In this study, the percentage of patients achieving a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief response (mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) 2 hours after treatment was statistically significantly greater in patients who received Almotriptan Malate tablets 6.25 mg or 12.5 mg compared with those who received placebo. There was no additional benefit on <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief provided by the 12.5 mg dose. The 2-hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief results are summarized in Table 4.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4. Response Rates 2 Hours Following Treatment of Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> in Adolescents Age 12 to 17 Years</span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="40%">
<thead><tr class="Botrule First Last">
<th align="left"></th>
<th align="left">Placebo</th>
<th align="left">Almotriptan Malate tablets 6.25 mg</th>
<th align="left">Almotriptan Malate tablets 12.5 mg</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>p value 0.001 in comparison with placebo</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>p value &lt;0.001 in comparison with placebo</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td align="left">Study 1</td>
<td align="left">55.3%<br>(n/N = 94/170)</td>
<td align="left">71.8%<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a><br>(n/N = 127/177)</td>
<td align="left">72.9%<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a><br>(n/N = 132/181)</td>
</tr></tbody>
</table>
<p>The estimated probability of achieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief within 2 hours following initial treatment with Almotriptan Malate tablets in adolescents age 12 to 17 years is shown in Figure 3.</p>
<p><span class="Bold">Figure 3.    Estimated Probability of Achieving an Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Response (Mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>) in 2 Hours in the Adolescent Study</span></p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-04.jpg"></p>
<p>The prevalence of the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>-associated symptoms (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span>) at 2 hours after taking the dose was not significantly different between patients who received Almotriptan Malate  6.25 mg or 12.5 mg tablets and those who received placebo.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Almotriptan Malate tablets are available as follows:</p>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">6.25 mg</span>: White, coated, circular, biconvex tablets with red code imprint "2080."</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="65%">
<tbody class="Headless">
<tr>
<td align="left"></td>
<td align="left" colspan="2">Unit Dose (aluminum <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)<br><br>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">6 tablets</td>
<td align="left">NDC 10147-0962-1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14.2"></a><p></p>
<p class="First"><span class="Bold">12.5 mg</span>: White, coated, circular, biconvex tablets with blue stylized imprint "A."</p>
<table class="Noautorules" width="50%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="30%">
<col align="left" valign="top" width="65%">
<tbody class="Headless">
<tr>
<td align="left"></td>
<td align="left" colspan="2">Unit Dose (aluminum <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack)<br><br>
</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">12 tablets</td>
<td align="left">NDC 10147-0961-1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.3"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
<div class="Section" data-sectionCode="34073-7">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Underline">Drug Interactions</span></p>
<p>Advise patients to talk with their physician or pharmacist before taking any new medicines, including prescription and non-prescription drugs and supplements <span class="Italics">[see <a href="#S4.5">Contraindications (4.5)</a> and <a href="#S4.6">(4.6)</a> and <a href="#S7">Drug Interactions (7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p>Inform patients to tell their physician if they develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, or breathing difficulties after taking Almotriptan Malate tablets <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Underline">Risk of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial Ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span>, Other Adverse Cardiac Events, Other <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">Vasospasm</span>-Related Events, and Cerebrovascular Events</span></p>
<p>Inform patients that Almotriptan Malate tablets may cause serious cardiovascular side effects such as <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or slurring of speech, and should ask for medical advice when observing any indicative signs or symptoms. Apprise the patient of the importance of this follow-up <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>, <a href="#S5.2">(5.2)</a>, <a href="#S5.3">(5.3)</a>, and <a href="#S5.4">(5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span></span></p>
<p>Caution patients about the risk of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with the use of Almotriptan Malate tablets or other triptans, particularly during combined use with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs) <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.5"></a><p></p>
<p class="First"><span class="Underline">Medication Overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </span></p>
<p>Inform patients that use of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">acute migraine</span> drugs for 10 or more days per month may lead to an exacerbation of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and encourage patients to record <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> frequency and drug use (e.g., by keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary) <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-15.6"></a><p></p>
<p class="First"><span class="Underline">Pregnancy</span></p>
<p>Advise patients to notify their physician if they become pregnant during treatment or intend to become pregnant <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-15.7"></a><p></p>
<p class="First"><span class="Underline">Nursing Mothers</span></p>
<p>Advise patients to notify their physician if they are breastfeeding or plan to breastfeed <span class="Italics">[see <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.8"></a><p></p>
<p class="First"><span class="Underline">Ability to Operate Machinery or Vehicles</span></p>
<p>Counsel patients that Almotriptan Malate tablets may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, and other CNS symptoms that can interfere with driving or operating machinery. Accordingly, advise the patient not to drive, operate complex machinery, or engage in other hazardous activities until they have gained sufficient experience with Almotriptan Malate tablets to gauge whether it affects their mental or visual performance adversely.</p>
<p>Product of Spain</p>
<p>Almotriptan Malate tablets are manufactured by:<br>Janssen-Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>Almotriptan Malate tablets are manufactured for:<br>Patriot Pharmaceuticals, LLC<br>Horsham, PA 19044</p>
<p>Licensed from: Almirall, S.A.<br>U.S. Patent No. 5,565,447</p>
<p>© Patriot Pharmaceuticals, LLC 2015 </p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First"><span class="Bold">Almotriptan Malate tablets</span></p>
<p>Please read this information before you start taking Almotriptan Malate tablets. Also, read this leaflet each time you renew your prescription just in case anything has changed. Remember, this leaflet does not take the place of careful discussions with your doctor. You and your doctor should discuss Almotriptan Malate tablets when you start taking your medication and at regular checkups.</p>
<p><span class="Bold">What are Almotriptan Malate tablets and what are they used for?</span></p>
<p>Almotriptan Malate tablets are medication used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in adults and adolescents age 12 to 17 years. Almotriptan Malate tablets are a member of a class of drugs called selective serotonin receptor agonists.</p>
<p>Use Almotriptan Malate tablets only for a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. Do not use Almotriptan Malate tablets to treat <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> that might be caused by other conditions. Tell your doctor about your symptoms. Your doctor will decide if you have <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p>There is more information about <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> at the end of this leaflet.</p>
<p><span class="Bold">Who should not take Almotriptan Malate tablets?<a name="footnote-reference-6" href="#footnote-6" class="Sup">1</a></span></p>
<p><span class="Bold">Do not take Almotriptan Malate tablets if you:</span></p>
<ul class="Disc">
<li>have ever had heart disease.</li>
<li>have uncontrolled high blood pressure.</li>
<li>have hemiplegic or basilar <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If you are not sure, ask your doctor.</li>
<li>have taken another serotonin receptor agonist (e.g., another triptan) in the last 24 hours. These include naratriptan (AMERGE<span class="Sup">®</span>), rizatriptan (MAXALT<span class="Sup">®</span>), sumatriptan (IMITREX<span class="Sup">®</span>, TREXIMET<span class="Sup">®</span>), or zolmitriptan (ZOMIG<span class="Sup">®</span>).</li>
<li>have taken ergotamine-type medicines in the last 24 hours. These include ergotamine (BELLERGAL-S<span class="Sup">®</span>, CAFERGOT<span class="Sup">®</span>, ERGOMAR<span class="Sup">®</span>, WIGRAINE<span class="Sup">®</span>), dihydroergotamine (D.H.E. 45<span class="Sup">®</span>), or methysergide (SANSERT<span class="Sup">®</span>).</li>
<li>had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Almotriptan Malate tablets or any of its ingredients. The active ingredient is almotriptan malate. Ask your doctor or pharmacist about inactive ingredients.</li>
</ul>
<p><span class="Bold">Tell your doctor if you take:</span></p>
<ul class="Disc">
<li> monoamine oxidase (MAO) inhibitors, such as phenelzine sulfate (NARDIL<span class="Sup">®</span>) or tranylcypromine sulfate (PARNATE<span class="Sup">®</span>) for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or another condition, or if it has been less than two weeks since you stopped taking an MAO inhibitor.</li>
<li> ketoconazole (NIZORAL<span class="Sup">®</span>), itraconazole (SPORANOX<span class="Sup">®</span>), ritonavir (NORVIR<span class="Sup">®</span>), or erythromycin (EMYCIN<span class="Sup">®</span>), or if it has been less than one week since you stopped taking one of these drugs.</li>
<li> selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), two types of drugs for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or other disorders. Common SSRIs are CELEXA<span class="Sup">®</span> (citalopram HBr), LEXAPRO<span class="Sup">®</span> (escitalopram oxalate), PAXIL<span class="Sup">®</span> (paroxetine), PROZAC<span class="Sup">®</span>/SARAFEM<span class="Sup">®</span> (fluoxetine), SYMBYAX<span class="Sup">®</span> (olanzapine/fluoxetine), ZOLOFT<span class="Sup">®</span> (sertraline), and fluvoxamine. Common SNRIs are CYMBALTA<span class="Sup">®</span> (duloxetine) and EFFEXOR<span class="Sup">®</span> (venlafaxine).</li>
</ul>
<p>These medicines may affect how Almotriptan Malate tablets work, or Almotriptan Malate tablets may affect how these medicines work.</p>
<p>To help your doctor decide if Almotriptan Malate tablets are right for you or if you need to be checked while taking Almotriptan Malate tablets, tell your doctor about any:</p>
<ul class="Disc">
<li>past or present medical problems.</li>
<li>past or present high blood pressure, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, or heart disease.</li>
<li>liver or kidney problems.</li>
<li>risk factors for heart disease, such as:<dl>
<dt>–</dt>
<dd>high blood pressure</dd>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></dd>
<dt>–</dt>
<dd>high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span></dd>
<dt>–</dt>
<dd>overweight</dd>
<dt>–</dt>
<dd>smoking</dd>
<dt>–</dt>
<dd>family members with heart disease</dd>
<dt>–</dt>
<dd>you are past <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span></dd>
<dt>–</dt>
<dd>you are a male over 40 years old.</dd>
</dl>
</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to sulfonamides, also known as sulfa drugs (ask your doctor if you are not sure what sulfonamide drugs are).</li>
<li> medicines you take or plan to take, including prescription and non-prescription medicines and herbal supplements. Be sure to include medicines you normally take for a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. </li>
</ul>
<p>Talk to your doctor about using Almotriptan Malate tablets if you are pregnant, planning to become pregnant, or breastfeeding.</p>
<p><span class="Bold">How should I take Almotriptan Malate tablets?</span></p>
<ul class="Disc">
<li>When you have a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>, take your medicine as directed by your doctor.</li>
<li>If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> comes back after your first dose, you may take a second dose 2 hours or more after the first dose. If your <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> continues after the first dose, do not take a second dose without first checking with your doctor.</li>
<li>Do not take more than two Almotriptan Malate tablets in a 24-hour period.</li>
<li>Some people who take <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> medicines, like Almotriptan Malate tablets, for 10 or more days every month may have worse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> (medication overuse <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>). If your <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> get worse, your healthcare provider may decide to stop your treatment with Almotriptan Malate tablets.</li>
<li>If you take too much medicine, contact your doctor, hospital emergency department, or poison control center right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking Almotriptan Malate tablets?</span></p>
<p>Check with your doctor before you take any new medicines, including prescription and non-prescription medicines and supplements. There are some medicines that you should not take during the period 24 hours before and 24 hours after taking Almotriptan Malate tablets. Some of them are listed in the section <span class="Bold">"Who should not take Almotriptan Malate tablets?"</span></p>
<p><span class="Bold">What are the possible side effects of Almotriptan Malate tablets?</span></p>
<p>The side effects are usually mild and do not last long. The following is <span class="Bold">not</span> a complete list of side effects. Ask your doctor to tell you about the other side effects.</p>
<p>The <span class="Bold">most common</span> side effects in adults are:</p>
<ul class="Disc">
<li> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> or burning feeling (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>)</li>
<li> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></li>
</ul>
<p>The <span class="Bold">most common</span> side effects in adolescents are:</p>
<ul class="Disc">
<li> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Sleepiness</span></li>
<li> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></li>
<li> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></li>
<li> <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Tingling</span> or burning feeling (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>)</li>
<li> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></li>
</ul>
<p>If you feel dizzy or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, or if you notice any changes in your vision, you should evaluate your ability to perform complex tasks, such as driving or operating heavy machinery.</p>
<p>Tell your doctor about any other symptoms that you develop while taking Almotriptan Malate tablets. If the symptoms continue or worsen, get medical help right away. Also, tell your doctor if you develop any of the following after taking Almotriptan Malate tablets:</p>
<ul class="Disc">
<li>a swollen face, lips, mouth, tongue or throat</li>
<li>difficulty swallowing or breathing</li>
<li>an <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>).</li>
</ul>
<p>These may be a sign that you are allergic to the medicine.</p>
<p>In very rare cases, patients taking this class of medicines experience serious heart problems, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>. Extremely rarely, patients have died. Therefore, tell your doctor right away if you feel tightness, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, pressure, or heaviness in your chest, throat, neck, or jaw after taking Almotriptan Malate tablets. Do not take Almotriptan Malate tablets again until your doctor has checked you.</p>
<p>Some people may have a reaction called <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, which can be life-threatening, when they use Almotriptan Malate tablets. In particular, this reaction may occur when they use Almotriptan Malate tablets together with certain types of antidepressants known as SSRIs or SNRIs. Symptoms may include mental changes (<span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), fast heartbeat, changes in blood pressure, high body temperature or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, tight muscles, trouble walking, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Call your doctor immediately if you have any of these symptoms after taking Almotriptan Malate tablets.</p>
<p>This is not a complete list of side effects. Talk to your doctor if you develop any symptoms that concern you.</p>
<p><span class="Bold">What to do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</span></p>
<p>Call your doctor or poison control center or go to the ER.</p>
<p><span class="Bold">What is a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> and how does it differ from other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>?</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> is an intense, throbbing, typically one-sided <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. It often includes <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, sensitivity to light, and sensitivity to sound. The <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and symptoms from a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> may be worse than the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and symptoms of a common <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Some people have visual symptoms before the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, such as <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">flashing lights</span> or wavy lines, called an <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> attacks typically last for hours or, rarely, for more than a day. They can return often. The strength and frequency of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks may vary.</p>
<p>Based on your symptoms, your doctor will decide whether you have a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine headaches</span> tend to occur in members of the same family. Both men and women get <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, but it is more common in women.</p>
<p><span class="Bold">What may trigger a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack?</span></p>
<p>Certain things may trigger <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in some people. Some of these triggers are:</p>
<ul class="Disc">
<li>certain foods or drinks, such as cheese, chocolate, citrus fruit (oranges, grapefruit, lemons, limes, and others), caffeine, and alcohol.</li>
<li>stress.</li>
<li>a change in behavior, such as too much or too little sleep, missing a meal, or a change in diet.</li>
<li>hormone changes in women, such as during monthly menstrual periods.</li>
</ul>
<p>You may be able to prevent <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks or make them come less often if you understand what triggers your attacks. Keeping a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> diary may help you identify and monitor the possible triggers that cause your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. Once you identify the triggers, you and your doctor can change your lifestyle to avoid those triggers.</p>
<p><span class="Bold">How do Almotriptan Malate tablets work during a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack?</span></p>
<p><span class="Bold">Treatment with Almotriptan Malate tablets:</span></p>
<ul class="Disc">
<li>reduces <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of blood vessels surrounding the brain. This <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> is associated with the <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack.</li>
<li>blocks the release of substances from nerve endings that cause more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and other symptoms of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.</li>
<li>interrupts the sending of specific <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> signals to your brain.</li>
</ul>
<p>It is thought that each of these actions contributes to relief of your symptoms by Almotriptan Malate tablets.</p>
<p><span class="Bold">How should I store Almotriptan Malate tablets?</span></p>
<p>Keep your medicine in a safe place where children cannot reach it. It may be harmful to children. Store your medicine away from heat, light, or moisture at a controlled room temperature. If your medicine has expired, throw it away as instructed. If your doctor decides to stop your treatment, do not keep any leftover medicine unless your doctor tells you to do so. Throw away your medicine as instructed. Be sure that discarded tablets are out of the reach of children.</p>
<p><span class="Bold">General advice about prescription medicines</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not use Almotriptan Malate tablets for a condition for which they are not prescribed. Do not give Almotriptan Malate tablets to other people even if they have the same symptoms you have. People may be harmed if they take medicines that have not been prescribed for them.</p>
<p>This leaflet provides a summary of information about Almotriptan Malate tablets. If you have any questions or concerns about either Almotriptan Malate tablets or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, talk to your doctor. In addition, talk to your pharmacist or other healthcare provider.</p>
<p>Product of Spain</p>
<p>Almotriptan Malate tablets are manufactured by:<br>Janssen-Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>Almotriptan Malate tablets are manufactured for:<br>Patriot Pharmaceuticals, LLC<br>Horsham, PA 19044</p>
<p>Licensed from: Almirall, S.A.<br>U.S. Patent No. 5,565,447</p>
<p>© Patriot Pharmaceuticals, LLC 2015</p>
<p>Revised January 2015</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">1</a></dt>
<dd>The brands listed are the trademarks of their respective owners and are not the trademarks of Janssen Pharmaceuticals, Inc.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 6 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Box</h1>
<p class="First">NDC 10147-0962-1</p>
<p><span class="Bold">Almotriptan<br>Malate tablets</span></p>
<p>equivalent to<br><span class="Bold">6.25 mg</span><br>almotriptan</p>
<p>6 tablets<br>Rx only</p>
<p><span class="Bold">PATRIOT</span><br>PHARMACEUTICALS LLC</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 6 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 12 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Box</h1>
<p class="First">NDC 10147-0961-1</p>
<p><span class="Bold">Almotriptan<br>Malate tablets</span></p>
<p>equivalent to<br><span class="Bold">12.5 mg</span><br>almotriptan</p>
<p>12 tablets<br>Rx only</p>
<p><span class="Bold">PATRIOT</span><br>PHARMACEUTICALS LLC</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 12 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9129bb95-7846-4ed7-bd03-0c17d8963447&amp;name=almotriptan-06.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALMOTRIPTAN MALATE 		
					</strong><br><span class="contentTableReg">almotriptan malate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10147-0962</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Almotriptan Malate</strong> (Almotriptan) </td>
<td class="formItem">Almotriptan</td>
<td class="formItem">6.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">2080</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10147-0962-1</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021001</td>
<td class="formItem">07/07/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ALMOTRIPTAN MALATE 		
					</strong><br><span class="contentTableReg">almotriptan malate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:10147-0961</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Almotriptan Malate</strong> (Almotriptan) </td>
<td class="formItem">Almotriptan</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>powdered cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>fd&amp;c blue no. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidones</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium stearyl fumarate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">A</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:10147-0961-1</td>
<td class="formItem">2  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">6  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021001</td>
<td class="formItem">07/07/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Patriot Pharmaceuticals, LLC
							(178220385)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Janssen Pharmaceuticals Inc (063137772)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen-Ortho LLC</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">ANALYSIS(10147-0962, 10147-0961), MANUFACTURE(10147-0962, 10147-0961)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Ranke Quimica, S.L.</td>
<td class="formItem"></td>
<td class="formItem">563076157</td>
<td class="formItem">API MANUFACTURE(10147-0962, 10147-0961)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8819a2e0-bfc9-43a2-9f15-06784752746a</div>
<div>Set id: 9129bb95-7846-4ed7-bd03-0c17d8963447</div>
<div>Version: 1</div>
<div>Effective Time: 20150709</div>
</div>
</div> <div class="DistributorName">Patriot Pharmaceuticals, LLC</div></p>
</body></html>
